StockData
Neogen Corp logo

Neogen Corp (NEOG) stock

NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$10.55−0.30 (-2.76%)

Close on Nov 20, 2026Market cap $2.30BP/E –Yield –

Neogen free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Neogen's free cash flow for the twelve months ending Aug 31, 2026 was $49.80M. For fiscal 2026 it was $31.90M. Over ten years it grew 4.2% a year on average. The highest annual figure on record is $61.83M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2026May 31, 2026$31.90M–
FY2025May 31, 2025-$46.40M–
FY2024May 31, 2024-$76.10M–
FY2023May 31, 2023-$24.73M-156.7%
FY2022May 31, 2022$43.61M-19.8%
FY2021May 31, 2021$54.38M-12.0%
FY2020May 31, 2020$61.83M+25.7%
FY2019May 31, 2019$49.18M+2.1%
FY2018May 31, 2018$48.19M+5.4%
FY2017May 31, 2017$45.70M+116.5%
FY2016May 31, 2016$21.11M-38.2%
FY2015May 31, 2015$34.17M+237.5%
FY2014May 31, 2014$10.13M-42.7%
FY2013May 31, 2013$17.66M+79.1%
FY2012May 31, 2012$9.86M-53.1%
FY2011May 31, 2011$21.05M-6.7%
FY2010May 31, 2010$22.56M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ3 2026Aug 31, 2026$4.70M–
Q4 FY2026CQ2 2026May 31, 2026$26.20M+8633.3%
Q3 FY2026CQ1 2026Feb 28, 2026$11.07M–
Q2 FY2026CQ4 2025Nov 30, 2025$7.83M-66.1%
Q1 FY2026CQ3 2025Aug 31, 2025-$13.20M–
Q4 FY2025CQ2 2025May 31, 2025$300.00K-88.2%
Q3 FY2025CQ1 2025Feb 28, 2025-$13.45M–
Q2 FY2025CQ4 2024Nov 30, 2024$23.10M–
Q1 FY2025CQ3 2024Aug 31, 2024-$56.35M–
Q4 FY2024CQ2 2024May 31, 2024$2.55M-96.1%
Q3 FY2024CQ1 2024Feb 29, 2024-$62.33M–
Q2 FY2024CQ4 2023Nov 30, 2023-$8.70M–
Q1 FY2024CQ3 2023Aug 31, 2023-$7.62M–
Q4 FY2023CQ2 2023May 31, 2023$65.46M+733.7%
Q3 FY2023CQ1 2023Feb 28, 2023-$32.22M–
Q2 FY2023CQ4 2022Nov 30, 2022-$30.83M-321.7%
Q1 FY2023CQ3 2022Aug 31, 2022-$27.14M-223.8%
Q4 FY2022CQ2 2022May 31, 2022$7.85M-46.4%
Q3 FY2022CQ1 2022Feb 28, 2022-$65.00K-102.0%
Q2 FY2022CQ4 2021Nov 30, 2021$13.91M-10.5%
Q1 FY2022CQ3 2021Aug 31, 2021$21.92M+4.9%
Q4 FY2021CQ2 2021May 31, 2021$14.65M-18.1%
Q3 FY2021CQ1 2021Feb 28, 2021$3.30M-79.7%
Q2 FY2021CQ4 2020Nov 30, 2020$15.55M+49.3%
Q1 FY2021CQ3 2020Aug 31, 2020$20.89M+21.1%
Q4 FY2020CQ2 2020May 31, 2020$17.90M-1.1%
Q3 FY2020CQ1 2020Feb 29, 2020$16.26M+211.2%
Q2 FY2020CQ4 2019Nov 30, 2019$10.42M-11.0%
Q1 FY2020CQ3 2019Aug 31, 2019$17.25M+21.8%
Q4 FY2019CQ2 2019May 31, 2019$18.09M+1.0%
Q3 FY2019CQ1 2019Feb 28, 2019$5.23M-60.7%
Q2 FY2019CQ4 2018Nov 30, 2018$11.70M+326.7%
Q1 FY2019CQ3 2018Aug 31, 2018$14.16M-0.6%
Q4 FY2018CQ2 2018May 31, 2018$17.91M+32.5%
Q3 FY2018CQ1 2018Feb 28, 2018$13.28M+49.6%
Q2 FY2018CQ4 2017Nov 30, 2017$2.74M-57.7%
Q1 FY2018CQ3 2017Aug 31, 2017$14.26M–
Q4 FY2017CQ2 2017May 31, 2017$13.51M–
Q3 FY2017CQ1 2017Feb 28, 2017$8.88M–
Q2 FY2017CQ4 2016Nov 30, 2016$6.48M–

More Neogen figures

See a number that looks wrong?